<DOC>
	<DOCNO>NCT00210340</DOCNO>
	<brief_summary>The purpose study define safety profile rituximab give intrathecally lymphomatous meningitis relate CD20+ non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>A Phase I Study Intrathecal Rituximab Patients With Lymphomatous Meningitis</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Lymphomatous meningitis document positive CSF cytology either newly diagnose , relapse refractory primary CNS systemic NHL 2 . Pathologically diagnosed CD20positive NHL 3 . Age â‰¥ 18 year 4 . ECOG Performance Status 0 2 ( See Appendix A ) 5 . Life expectancy least 1 month 6 . Informed consent must give accord national/local regulation enrollment ( See Appendix B ) 7 . Patients may prior CNS irradiation , intrathecal methotrexate , cytarabine thiotepa treatment lymphomatous meningitis treatment must complete least two week study enrollment patient must recover reversible toxicity cause prior treatment 8 . Concurrent systemic chemotherapy allow exception highdose methotrexate ( &gt; 500 mg/m2/day ) , highdose cytarabine ( &gt; 2 g/m2/day ) , highdose thiotepa ( &gt; 300 mg/m2/day ) investigational agent 9 . No concurrent intrathecal chemotherapy rituximab 10 . No severe impairment bone marrow function ( ANC &gt; 1.5x109/L , PLT &gt; 50x109/L ) , unless due proven lymphoma involvement 11 . No major impairment renal function ( serum creatinine &lt; 1,5 x upper normal ) liver function ( ASAT/ALAT &lt; 2,5 upper normal , total bilirubin &lt; 2,5x upper normal ) , unless due proven lymphoma involvement 12 . No evidence active opportunistic infection 13 . No HIV infection 14 . No pregnant lactating status 15 . Appropriate contraceptive method woman childbearing potential men 16 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial 17 . Absence obstructive hydrocephalus compartimentalization CSF flow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>